(Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors
US9944601B2 · kind B2 · utility
4Cited by
30References
19Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 21, 2016 |
| Grant date | Apr 17, 2018 |
| Priority date | — |
| Expiry date | Sep 21, 2036 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D451/04
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The invention relates to (hetero)aryl cyclopropylamine compounds, including particularly the compounds of formula I as described and defined herein, and their use in therapy, including, e.g., in the treatment or prevention of cancer, a neurological disease or condition, or a viral infection.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.